Tenon Medical Inc (TNON)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $3.79M
Last updated: Nov 17, 2026 at 11:03 AM ET
Tenon Medical Inc (TNON) Earnings: Report Dates and Results
Tenon Medical (TNON) is expected to report earnings on Mar 17, 2027. In the quarter ended Sep 30, 2026, Tenon Medical reported EPS of -$5.39, below the -$4.23 estimate. It beat the EPS estimate in 3 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
TNON has an expected report date of Mar 17, 2027.
TNON Earnings Call
The latest TNON earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 18 quarters below that had an estimate, TNON beat 11 and missed 7. Revenue for the quarter ended Sep 30, 2026 was $1.43M, up 22.2% from $1.17M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$5.39 | -$4.23 | -$5.62 - -$2.83 | -27.57% | Miss | N/A | 2 | 0 up, 0 down | Nov 12, 2026 | $1.43M |
| Jun 30, 2026 | -$12.35 | -$8.40 | -$9.45 - -$7.35 | -47.02% | Miss | N/A | 2 | 1 up, 1 down | Aug 13, 2026 | $1.28M |
| Mar 31, 2026 | -$10.85 | -$10.68 | -$11.89 - -$9.44 | -1.64% | Miss | N/A | 2 | 2 up, 0 down | May 12, 2026 | $1.38M |
| Dec 31, 2025 | -$0.22 | -$0.36 | N/A | +38.89% | Beat | N/A | 2 | 0 up, 0 down | Mar 19, 2026 | $1.48M |
| Sep 30, 2025 | -$0.40 | -$0.37 | -$0.39 - -$0.35 | -8.11% | Miss | N/A | 2 | 0 up, 0 down | Nov 13, 2025 | $1.17M |
| Jun 30, 2025 | -$0.36 | -$0.47 | -$0.47 - -$0.47 | +23.40% | Beat | N/A | 2 | 0 up, 0 down | Aug 13, 2025 | $564000 |
| Mar 31, 2025 | -$1.01 | -$0.92 | -$0.92 - -$0.92 | -9.78% | Miss | N/A | 1 | 1 up, 0 down | May 13, 2025 | $726000 |
| Dec 31, 2024 | -$0.98 | -$3.77 | -$3.77 - -$3.77 | +73.91% | Beat | N/A | 1 | 1 up, 0 down | Mar 20, 2025 | $770000 |
| Sep 30, 2024 | -$3.63 | -$6.16 | -$6.16 - -$6.16 | +41.07% | Beat | N/A | 1 | 1 up, 0 down | Nov 13, 2024 | $887000 |
| Jun 30, 2024 | -$1.02 | -$1.09 | -$1.20 - -$0.97 | +5.99% | Beat | N/A | 2 | 0 up, 0 down | Aug 13, 2024 | $901000 |
| Mar 31, 2024 | -$10.00 | -$10.72 | -$11.60 - -$9.84 | +6.72% | Beat | N/A | 2 | 0 up, 0 down | May 14, 2024 | $719000 |
| Dec 31, 2023 | -$0.68 | -$1.38 | -$1.66 - -$1.10 | +50.72% | Beat | N/A | 2 | 0 up, 0 down | Mar 12, 2024 | $808000 |
| Sep 30, 2023 | -$11.68 | -$22.40 | N/A | +47.86% | Beat | N/A | 2 | 0 up, 0 down | Nov 14, 2023 | $944000 |
| Jun 30, 2023 | -$26.40 | -$30.40 | -$30.40 - -$30.40 | +13.16% | Beat | N/A | 1 | 0 up, 0 down | Aug 8, 2023 | $743000 |
| Mar 31, 2023 | -$0.43 | -$0.37 | -$0.37 - -$0.37 | -16.22% | Miss | N/A | 1 | 0 up, 0 down | May 9, 2023 | $433000 |
| Dec 31, 2022 | -$56.00 | -$64.80 | N/A | +13.58% | Beat | N/A | N/A | 0 up, 0 down | Mar 9, 2023 | $277000 |
| Sep 30, 2022 | -$22.40 | -$37.60 | -$37.60 - -$37.60 | +40.43% | Beat | N/A | 1 | 0 up, 0 down | Nov 10, 2022 | $208000 |
| Jun 30, 2022 | -$39.07 | -$16.00 | N/A | -144.19% | Miss | N/A | N/A | 0 up, 0 down | Aug 11, 2022 | $135000 |
| Mar 31, 2022 | -$0.25 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Apr 27, 2022 | $71000 |
| Sep 30, 2021 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 10, 2021 | $70000 |
| Jun 30, 2021 | -$0.17 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 30, 2021 | $22000 |
Estimates made before a stock split are shown on the same share basis as the reported EPS.
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$1.99, after -$15.63 the year before. It was -$117.91 for the year ended Dec 31, 2022, the oldest of the 4 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$1.99 | N/A |
| Dec 31, 2024 | -$15.63 | N/A |
| Dec 31, 2023 | -$39.19 | N/A |
| Dec 31, 2022 | -$117.91 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 2,100 words across 3 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 2,144 | 3 | |
| 2026Q2 | Jun 30, 2026 | 2,449 | 4 | |
| 2026Q1 | Mar 31, 2026 | 3,296 | 5 | |
| 2025Q4 | Dec 31, 2025 | 3,194 | 5 | |
| 2025Q3 | Sep 30, 2025 | 4,044 | 5 | |
| 2025Q2 | Jun 30, 2025 | 3,052 | 5 | |
| 2025Q1 | Mar 31, 2025 | 3,321 | 5 | |
| 2024Q3 | Sep 30, 2024 | 3,094 | 4 |
2026Q3 Earnings Call
Opening remarks
Steven Foster President and Chief Executive Officer Thank you, Joe, and good afternoon, everyone. I am pleased to welcome you to today's third quarter 2026 financial results and corporate update conference call for Tenon Medical. Third quarter revenue was $1.4 million, an increase of 22% over the third quarter of last year and 12% sequentially from the second quarter. Gross profit was $1 million, an increase of 23% over the prior-year period. Gross margin was 66.3%, an improvement of 0.4 percentage points compared to 65.9% a year ago. We delivered this growth while reducing operating expenses compared to both the third quarter of 2025 and the second quarter of this year, improving our loss from operations in the period compared to both prior periods. Looking at the first nine months as a whole, revenue was $4.1 million, an increase of 66% from the $2.5 million in the first nine months of 2025. Gross profit was $2.7 million, more than double the $1.3 million in the prior-year period, at a gross margin of 66.2% compared with 54.4%. Growth on the top line came from continued adoption of our Catamaran and Symmetry platforms, and we completed more cases with more physician users in the quarter compared to the third quarter of 2025 and the second quarter of this year. Physician and distributor training remains a leading indicator for us, with 36 combined training activities completed within the quarter. The improvement in gross margin was primarily driven by two factors: higher revenue, which continues to absorb fixed costs, and the benefit of lower cost of sales within our Catamaran platform, driven by the 510(k) clearance we announced in early Q3, which reclassified certain instrumentation to reusable status. We believe both factors will continue to have a positive impact on our gross margins as we continue to grow. Beyond the financials, a few items from the quarter are worth noting. First, on the commercial side, our investments are focused on the commercial aspect of our business. As such, we have introduced a new commercial leader to the organization. Mr. Thomas Batten Jr. joined Tenon as Chief Revenue Officer, effective October 1, 2026. Tom brings significant experience building commercial teams in corporate roles, as well as experience as an independent distributor, with particular expertise in the sacropelvic space. We plan to continue adding to our commercial organization under Tom through the hiring of direct sales representatives and onboarding of independent distributor partners as we move forward. This move also allows us to deploy other team members to focus on the important product launches we are planning through the first half of 2027.
Frequently Asked Questions About TNON
When is Tenon Medical's next earnings date?
Tenon Medical's next earnings report is expected for Mar 17, 2027.
Did TNON beat earnings estimates last quarter?
No. Tenon Medical reported EPS of -$5.39 for the quarter ended Sep 30, 2026, below the -$4.23 estimate by 27.57%.
What EPS do analysts expect from TNON next quarter?
The consensus EPS estimate for Tenon Medical for the quarter ending Dec 31, 2026 is -$2.00 from 4 analysts, with estimates from -$2.35 to -$1.60.
How often does TNON beat earnings estimates?
Tenon Medical beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of +5.26%.
TNON pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors